

MATERIALS LICENSE

Amendment No. 34

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

301862

Licensee		In accordance with the application dated September 3, 1996	
1. Lorain Community/St. Joseph Regional Health Center		3. License Number 34-04474-01 is amended in its entirety to read as follows:	
2. 3700 Kolbe Road Lorain, OH 44053		4. Expiration Date November 30, 2004	
		5. Docket or Reference No. 030-02729	
6. Byproduct, Source, and/or Special Nuclear Material	7. Chemical and/or Physical Form	8. Maximum Amount that Licensee May Possess at Any One Time Under This License	
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed	
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200	B. As needed	
C. Any byproduct material identified in 10 CFR 35.300	C. Any radiopharmaceutical identified in 10 CFR 35.300	C. As needed (not to exceed 1 curie of iodine-131)	
D. Any byproduct material identified in 10 CFR 35.400	D. Any brachytherapy sources identified in 10 CFR 35.400	D. As needed	
E. Any byproduct material identified in 10 CFR 31.11	E. Prepackaged Kits	E. As needed	

9. Authorized Use:

- A. Medical use described in 10 CFR 35.100.
- B. Medical use described in 10 CFR 35.200.
- C. Medical use described in 10 CFR 35.300.

210059

9610210270 961003
PDR ADDCK 03002729
C PDRCOPY 230
50

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number

34-04474-01

Docket or Reference Number

030-02729

Amendment No. 34

9. Authorized Use (Continued)

- D. Medical use described in 10 CFR 35.400.
- E. In vitro studies.

CONDITIONS

10. A. Licensed material in Items 6.A. through 6.E. may be used at the licensee's East Campus facilities located at 205 West 20th Street, Lorain, Ohio.
- B. Licensed material in Items 6.A., 6.B., 6.C. and 6.E. may be used at the licensee's West Campus facilities located at 3700 Kolbe Road, Lorain, Ohio.
- C. Licensed material in Items 6.A., 6.B. (excluding generators) and 6.E. may be used at the licensee's facilities located at Allen Memorial Hospital, Oberlin, Ohio.
11. A. The Radiation Safety Officer for material in Items 6.A., 6.B., 6.C. and 6.E. is Thomas R. Martin, M.D.
- B. The Radiation Safety Officer for material in Item 6.D. is Mark Thompson, D.O.
12. Licensed material listed in Item 6 above is only authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

Authorized UsersMaterial and Use

- | | |
|-----------------------------------|---|
| A. David B. Joyce, M.D. | 10 CFR 35.200, limited to cardiovascular clinical procedures. |
| B. Lawrence G. Thorley, M.D. | 10 CFR 35.100, 35.200, 35.300, 35.400 and 31.11. |
| C. Carlos E. Fernandez Pena, M.D. | 10 CFR 35.100, 35.200, 35.300, 35.400 and 31.11. |
| D. Thomas K. Wu, M.D. | 10 CFR 35.100 and 35.200. |
| E. Thomas R. Martin, M.D. | 10 CFR 35.100, 35.200, 35.300, and 31.11. |
| F. Paul F. Varley, M.D. | 10 CFR 35.100, 35.200, 35.300, and 31.11. |
| G. Stephen M. Ticich, M.D. | 10 CFR 35.100, 35.200, 35.300, and 31.11. |
| H. John A. Vanek, M.D. | 10 CFR 35.100, 35.200, 35.300, and 31.11. |

COPY

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number

34-04474-01

Docket or Reference Number

030-02729

Amendment No. 34

12. (Continued)

Authorized UsersMaterial and Use

I. Teresita S. Ocampo, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11.
J. Richard L. Lenhart, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11.
K. Chadralekha P. Patel, M.D.	10 CFR 35.400.
L. Edwardo P. Martinez, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11.
M. William Ferber, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11.
N. Fredrich H. Dengel, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11.
O. Francis M. Kearney, M.D.	10 CFR 35.100, 35.200, 35.300, and 31.11.
P. Cathy H. Miller, M.D.	10 CFR 35.100, 35.200, 35.300, and 31.11.
Q. Peter Fanton, D.O.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11.
R. Timothy James Woisnet, M.D.	10 CFR 35.100, 35.200, and 31.11.
S. Eric C. Flint, M.D.	10 CFR 35.100, 35.200 and 31.11.
T. Brian Higgins, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11.
U. David P. Stout, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11.
V. Mark E. Thompson, D.O.	10 CFR 35.300, limited to Sr-89 for treatment of bone metastases, 35.400 and 31.11.
W. James G. Carlisle, M.D.	10 CFR 35.100, 35.200 and 35.300.
X. Paresh Arora, M.D.	10 CFR 35.100, 35.200 and 35.300.

COPY

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number

34-04474-01

Docket or Reference Number

030-02729

Amendment No. 34

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. The licensee is authorized to transport licensed material only in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
15. The licensee may transfer and transport licensed material in Items 6.A., 6.B., (excluding generators) and 6.E. between its facilities listed in Condition No. 10 in accordance with the statements, representations and procedures in the applications dated July 19, 1994 (with attachments), November 22, 1995 (with attachments) and letter dated May 23, 1996 (with attachments).
16. Vehicles used for transporting radioactive materials shall be promptly surveyed for contamination after each transfer.
17. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
 - A. Applications dated July 19, 1994 (with attachments), August 26, 1994 and November 22, 1995 (with attachments); and
 - B. Letters dated November 10, 1994, November 21, 1994, and May 23, 1996 (with attachments).

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date

10/3/96

By

Michael F. Webb

Nuclear Materials Licensing Branch, Region III

COPY

BETWEEN:

License Fee Management Branch, ARM
and
Regional Licensing Sections

(FOR LFMS USE)
INFORMATION FROM LTS

Program Code: 02120
Status Code: 0
Fee Category: 7C 2B
Exp. Date: 20041130
Fee Comments:
Decom Fin Assur Req'd: N

LICENSE FEE TRANSMITTAL

A. REGION

1. APPLICATION ATTACHED

Applicant/Licensee: LORAIN COMMUNITY/ST. JOSEPH
Received Date: 960923
Docket No: 3002729
Control No.: 301862
License No.: 34-04474-01
Action Type: Amendment

2. FEE ATTACHED

Amount: 440
Check No.: 16151

3. COMMENTS

Signed
Date

D. Hersey
9-14-96

B. LICENSE FEE MANAGEMENT BRANCH (Check when milestone 03 is entered /)

1. Fee Category and Amount:

7C 2B

440

2. Correct Fee Paid. Application may be processed for:

Amendment
Renewal
License

3. OTHER

Signed
Date

SC
9/30/96

OCT 08 1996

Log	Sep 11 711
Remitter	
Check No.	101151
Amount	440
Fee Category	7C 2B
Type of Fee	Amnd
Date Check Rec'd	9/27/96
Date Completed	9/30/96
By:	SC

APPLICATION FOR MATERIAL LICENSE

ESTIMATED BURDEN PER RESPONSE TO COMPLY WITH THIS INFORMATION COLLECTION REQUEST: 8 HOURS. SUBMITTAL OF THE APPLICATION IS NECESSARY TO DETERMINE THAT THE APPLICANT IS QUALIFIED AND THAT ADEQUATE PROCEDURES EXIST TO PROTECT THE PUBLIC HEALTH AND SAFETY. FORWARD COMMENTS REGARDING BURDEN ESTIMATE TO THE INFORMATION AND RECORDS MANAGEMENT BRANCH (MMRB 7714), U.S. NUCLEAR REGULATORY COMMISSION, WASHINGTON, DC 20555-0001, AND TO THE PAPERWORK REDUCTION PROJECT (3150-0120), OFFICE OF MANAGEMENT AND BUDGET, WASHINGTON, DC 20503.

INSTRUCTIONS: SEE THE APPROPRIATE LICENSE APPLICATION GUIDE FOR DETAILED INSTRUCTIONS FOR COMPLETING APPLICATION. SEND TWO COPIES OF THE ENTIRE COMPLETED APPLICATION TO THE NRC OFFICE SPECIFIED BELOW.

APPLICATION FOR DISTRIBUTION OF EXEMPT PRODUCTS FILE APPLICATIONS WITH:

DIVISION OF INDUSTRIAL AND MEDICAL NUCLEAR SAFETY
OFFICE OF NUCLEAR MATERIALS SAFETY AND SAFEGUARDS
U.S. NUCLEAR REGULATORY COMMISSION
WASHINGTON, DC 20555-0001

ALL OTHER PERSONS FILE APPLICATIONS AS FOLLOWS:

IF YOU ARE LOCATED IN:

CONNECTICUT, DELAWARE, DISTRICT OF COLUMBIA, MAINE, MARYLAND,
MASSACHUSETTS, NEW HAMPSHIRE, NEW JERSEY, NEW YORK, PENNSYLVANIA,
RHODE ISLAND, OR VERMONT, SEND APPLICATIONS TO:

LICENSING ASSISTANT SECTION
NUCLEAR MATERIALS SAFETY BRANCH
U.S. NUCLEAR REGULATORY COMMISSION, REGION I
475 ALLENDALE ROAD
KING OF PRUSSIA, PA 19406-1415

ALABAMA, FLORIDA, GEORGIA, KENTUCKY, MISSISSIPPI, NORTH CAROLINA, PUERTO
RICO, SOUTH CAROLINA, TENNESSEE, VIRGINIA, VIRGIN ISLANDS, OR WEST VIRGINIA,
SEND APPLICATIONS TO:

NUCLEAR MATERIALS LICENSING SECTION
U.S. NUCLEAR REGULATORY COMMISSION, REGION II
101 MARIETTA STREET, NW, SUITE 2900
ATLANTA, GA 30323-0199

PERSONS LOCATED IN AGREEMENT STATES SEND APPLICATIONS TO THE U.S. NUCLEAR REGULATORY COMMISSION ONLY IF THEY WISH TO POSSESS AND USE LICENSED MATERIAL IN STATES SUBJECT TO U.S. NUCLEAR REGULATORY COMMISSION JURISDICTIONS.

IF YOU ARE LOCATED IN:

ILLINOIS, INDIANA, IOWA, MICHIGAN, MINNESOTA, MISSOURI, OHIO, OR WISCONSIN,
SEND APPLICATIONS TO:

NUCLEAR MATERIALS LICENSING SECTION
U. S. NUCLEAR REGULATORY COMMISSION
REGION III
801 WARRENVILLE ROAD
LITSL, IL 60532-4351

ARKANSAS, COLORADO, IDAHO, KANSAS, LOUISIANA, MONTANA, NEBRASKA, NEW
MEXICO, NORTH DAKOTA, OKLAHOMA, SOUTH DAKOTA, TEXAS, UTAH, OR WYOMING,
SEND APPLICATIONS TO:

NUCLEAR MATERIALS LICENSING SECTION
U.S. NUCLEAR REGULATORY COMMISSION, REGION IV
811 RYAN PLAZA DRIVE, SUITE 400
ARLINGTON, TX 76011-8064

ALASKA, ARIZONA, CALIFORNIA, HAWAII, NEVADA, OREGON, WASHINGTON, AND U.S.
TERRITORIES AND POSSESSIONS IN THE PACIFIC, SEND APPLICATIONS TO:

RADIOACTIVE MATERIALS SAFETY BRANCH
U.S. NUCLEAR REGULATORY COMMISSION, REGION V
1450 MARIA LANE
WALNUT CREEK, CA 94596-5305

1. THIS IS AN APPLICATION FOR (Check appropriate item)

- ☐ A. NEW LICENSE
☒ B. AMENDMENT TO LICENSE NUMBER 34-04474-01
☐ C. RENEWAL OF LICENSE NUMBER _____

2. NAME AND MAILING ADDRESS OF APPLICANT (Include Zip code)

Lorain Community/St. Joseph Regional
Health Center
3700 Kolbe Road
Lorain, Ohio 44053

3. ADDRESS(ES) WHERE LICENSED MATERIAL WILL BE USED OR POSSESSED

Same

4. NAME OF PERSON TO BE CONTACTED ABOUT THIS APPLICATION

Frank T. Bloer, Consultant
Assoc. in Medical Physics, LLC
TELEPHONE NUMBER
(216) 581-4350

SUBMIT ITEMS 5 THROUGH 11 ON 8-1/2 X 11" PAPER. THE TYPE AND SCOPE OF INFORMATION TO BE PROVIDED IS DESCRIBED IN THE LICENSE APPLICATION GUIDE.

5. RADIOACTIVE MATERIAL. a. Element and mass number; b. chemical and/or physical form; and c. maximum amount which will be possessed at any one time.	6. PURPOSE(S) FOR WHICH LICENSED MATERIAL WILL BE USED.
7. INDIVIDUAL(S) RESPONSIBLE FOR RADIATION SAFETY PROGRAM AND THEIR TRAINING EXPERIENCE. See attached Item #7	8. TRAINING FOR INDIVIDUALS WORKING IN OR FREQUENTING RESTRICTED AREAS.
9. FACILITIES AND EQUIPMENT.	10. RADIATION SAFETY PROGRAM.
11. WASTE MANAGEMENT.	12. LICENSEE FEES (See 10 CFR 170 and Section 170.31) FEE CATEGORY <u>7C</u> AMOUNT ENCLOSED <u>\$440.00</u>
13. CERTIFICATION. (Must be completed by applicant) THE APPLICANT UNDERSTANDS THAT ALL STATEMENTS AND REPRESENTATIONS MADE IN THIS APPLICATION ARE BINDING UPON THE APPLICANT. THE APPLICANT AND ANY OFFICIAL EXECUTING THIS CERTIFICATION ON BEHALF OF THE APPLICANT, NAMED IN ITEM 2, CERTIFY THAT THIS APPLICATION IS PREPARED IN CONFORMITY WITH TITLE 10, CODE OF FEDERAL REGULATIONS, PARTS 30, 32, 33, 34, 35, 36, 39 AND 40, AND THAT ALL INFORMATION CONTAINED HEREIN IS TRUE AND CORRECT TO THE BEST OF THEIR KNOWLEDGE AND BELIEF. WARNING: 18 U.S.C. SECTION 1001 ACT OF JUNE 25, 1948 62 STAT. 749 MAKES IT A CRIMINAL OFFENSE TO MAKE A WILLFULLY FALSE STATEMENT OR REPRESENTATION TO ANY DEPARTMENT OR AGENCY OF THE UNITED STATES AS TO ANY MATTER WITHIN ITS JURISDICTION.	

CERTIFYING OFFICER - TYPED/PRINTED NAME AND TITLE

SIGNATURE

DATE

Steve Cookson Director

Steve Cookson

30 Sep 96

FOR NRC USE ONLY

TYPE OF FEE	FEE LOG	FEE CATEGORY	AMOUNT RECEIVED	CHECK NUMBER	COMMENTS
			\$		
APPROVED BY				DATE	

RECEIVED

SEP 23 1996

30/862

REGION III

SEP 23 1996

Refer to Item No. 7, NRC Form 313

Please amend our license to add Dr. James Carlisle and Dr. Paresh Arora for authorized uses under 10 CFR 35.100, 35.200, and I-131 for treatment of hyperthyroidism and thyroid carcinoma.

For training and experience of the above physicians, please refer to the attached documentation for each.

Item #7
Prepared: 8/13/96
License #34-04474-01



STATE MEDICAL BOARD OF OHIO

77 South High Street, 17th Floor • Columbus, Ohio 43266-0315 • (614) 466-3934

Date: May 6, 1996

To: CARLISLE, James Gerald, MD

This is to notify you that you are now licensed to practice medicine or osteopathic medicine and surgery in the State of Ohio. The Board approved your request and your license number 70333 was issued on May 6, 1996. Your license will be effective until September 30, 1993.

A wallet card and wall certificate will be mailed to you in approximately 3 - 4 weeks.

Ohio law requires all physicians to register (renew) licenses by June 30th of every even numbered year. Applications are mailed approximately March 1st of each even numbered year. ALL PHYSICIANS LICENSED PRIOR TO THAT DATE WILL BE REQUIRED TO REGISTER AND PAY THE RENEWAL FEE, however, those physicians licensed after the date of renewal application mailing will not be required to register or pay the renewal fee until the next biennium. Ohio law also requires 100 hours of continuing medical education for renewal. Enclosed is a CME booklet outlining these requirements.

SECTION 4731.281, OHIO REVISED CODE REQUIRES WRITTEN NOTICE TO THE BOARD OF ANY CHANGE OF PRINCIPAL PRACTICE ADDRESS OR RESIDENCE ADDRESS WITHIN THIRTY DAYS OF THE CHANGE.

This notice authorizes you to make application for your narcotics permit. To make such application, contact:

Drug Enforcement Administration (DEA)
431 Howard St.
Detroit, Michigan 48266
(313) 234-4000

Any questions regarding your DEA registration must be directed to the DEA office above.

Questions regarding CME; wallet cards and wall certificates that have been lost, damaged or contain errors; name changes and address changes must be submitted in writing to the State Medical Board of Ohio at the above address. Wallet cards and wall certificates that have been damaged or contain errors must be returned to the Board at the above address in order to issue a duplicate.

Sincerely,

A handwritten signature in cursive script that reads "Penny McKenzie".

Penny McKenzie
Chief, Licensure

PM/dh



Oakwood Hospital

OAKWOOD HOSPITAL AND MEDICAL CENTER-DEARBORN
DEPARTMENT OF NUCLEAR MEDICINE

TO: JAMES CARLISLE, M.D.

FROM: TED PFEFFER *TP*
MANAGER, NUCLEAR MEDICINE

DATE: OCTOBER 24, 1995

RE: USER ON NRC LICENSE

ATTACHED IS A COPY OF FORM EXHIBIT 3 CONTINUED (PAGE EXH-7 ONLY) AND ALSO A COPY OF YOUR RADIATION EXPOSURE WHILE YOU WERE AT OAKWOOD.

A COPY OF THIS PAGE 7, YOUR ABR CERTIFICATE, AND STATE MEDICAL LICENSE ARE NEEDED IF YOU WISH TO BE ADDED TO A NRC LICENSE AS A USER. IF YOU ARE ADDED TO A LICENSE LATER THAN 5 YEARS AFTER GRADUATION YOU WILL NEED TO SHOW CONTINUING EDUCATION IN THE FIELD OF NUCLEAR MEDICINE. ONCE YOU ARE ON A LICENSE YOU CAN TRANSFER FROM ONE TO ANOTHER VERY EASILY.

GOOD LUCK TO YOU AND GIVE ME A CALL IF YOU HAVE ANY FURTHER QUESTIONS. MY NUMBER IS (313) 593-7320.

EXHIBIT 3 (Continued)

PROPOSED PHYSICIAN USER

CARLISLE, JAMES

PRECEPTOR STATEMENT (Continued)

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comment may be submitted in duplicate on separate sheets.) D
P-32 (Sodium)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES		
P-32 (Cobalt-60)	INTRACAVITARY TREATMENT		
I-131	TREATMENT OF THYROID CARCINOMA	5	
	TREATMENT OF HYPERTHYROIDISM	16	
Au-198	INTRACAVITARY TREATMENT		
Co-60 or Cs-137	INTERSTITIAL TREATMENT		
	INTRACAVITARY TREATMENT		
I-125 or Ir-192	INTERSTITIAL TREATMENT		
Co-60 or Cs-137	TELE THERAPY TREATMENT		
Sr-90	TREATMENT OF EYE DISEASE		
	RADIOPHARMACEUTICAL PREPARATION		
Mo-99/ Tc-99m	GENERATOR		
Sr-90/ Y-90	GENERATOR		
Tc-99m	REAGENT KITS		
Other			

3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

LOCATION

DATES

CLOCK HOURS OF EXPERIENCE

4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:

a. NAME OF SUPERVISOR

REZA ABGHARI, M.D.

b. NAME OF INSTITUTION

OAKWOOD HOSPITAL

c. MAILING ADDRESS

18101 OAKWOOD BLVD. BOX 2500


d. CITY

DEARBORN, MI 48123-2500

5. MATERIALS LICENSE NUMBER(S)

21-04515-01

6. PRECEPTOR'S SIGNATURE



7. PRECEPTOR'S NAME (Please type or print)

REZA ABGHARI, M.D.

8. DATE

OCTOBER 24, 1995

001 - 100

The American Board of Radiology

Organized through the cooperation of the
American College of Radiology, the American Roentgen Ray Society,
the American Radium Society, the Radiological Society of North America,
the Section on Radiology of the American Medical Association,
the American Society for Therapeutic Radiology and Oncology, the Association of
University Radiologists, and American Association of Physicists in Medicine

Thereby certifies that

James Gerald Farlinle, M.D.


Has pursued an accepted course of graduate study
and clinical work, has met certain standards and qualifications and
has passed the examinations conducted under the authority of

The American Board of Radiology

On this seventh day of June, 1995

Thereby demonstrating to the satisfaction of the Board
that he is qualified to practice the specialty of

Diagnostic Radiology



Laughlin Maynard MD
President

William J. Farrell MD
Executive Director

W. D. L. C. M.D.

TRAINING AND EXPERIENCE
AUTHORIZED USER OR RADIATION SAFETY OFFICER

1. NAME OF AUTHORIZED USER OR RADIATION SAFETY OFFICER

PARESH ARORA MD

2. STATE OR TERRITORY IN
WHICH LICENSED TO
PRACTICE MEDICINE

OHIO

3. CERTIFICATION

SPECIALTY BOARD
ACATEGORY
BMONTH AND YEAR CERTIFIED
CAMERICAN BOARD
OF RADIOLOGYDIAGNOSTIC
RADIOLOGY

11-7-95

4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES

FIELD OF TRAINING A	LOCATION AND DATE(S) OF TRAINING B	TYPE AND LENGTH OF TRAINING	
		LECTURE/ LABORATORY COURSES (Hours) C	SUPERVISED LABORATORY EXPERIENCE (Hours) D
a. RADIATION PHYSICS AND INSTRUMENTATION	Cleveland Clinic Foundation Diagnostic Radiology Residency 6 mos Total: Dec 1991		100
b. RADIATION PROTECTION	Mar 1992 Oct 1992 Mar 1994 Aug 1994		30
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY	Apr 1995		20
d. RADIATION BIOLOGY			20
e. RADIOPHARMACEUTICAL CHEMISTRY			30

5. EXPERIENCE WITH RADIATION. (Actual use of Radioisotopes or Equivalent Experience)

ISOTOPE	MAXIMUM AMOUNT	WHERE EXPERIENCE WAS GAINED	DURATION OF EXPERIENCE	TYPE OF USE
Tc 99m Tl 201 Ga 67 In 111 I 123 Co 57/58 I 131	25 mCi (bare Sr) 2-5 mCi 3-6 mCi 0.5 mCi 10-20 mCi uptake/100 5 mCi/injection 5 mCi uptake/50-100 mCi 200 mCi 15 mCi			DIAGNOSTIC
I 131 P 32				THERAPEUTIC

PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

1. APPLICANT PHYSICIAN'S NAME AND ADDRESS

FULL NAME

FARESH ARORA MD

STREET ADDRESS

221 EIGHTH ST
C/O RUSSELL BRIDGEBILL & ASSOC.

CITY

LORAIN, OH

STATE

ZIP CODE

44052

KEY TO COLUMN C

PERSONAL PARTICIPATION SHOULD CONSIST OF:

- 1-Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.
- 2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and timing of data.
- 3-Adequate period of training to enable physician to manage radioactive patients and follow-up patients through diagnosis and/or course of treatment.

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
I-131 or I-125	DIAGNOSIS OF THYROID FUNCTION		
	DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME		
	LIVER FUNCTION STUDIES		
	FAT ABSORPTION STUDIES		
	KIDNEY FUNCTION STUDIES (Tc 99m)	488	
	IN VITRO STUDIES		
OTHER	In III WBC Scan	11	
I-125	DETECTION OF THROMBOSIS		
I-131	THYROID IMAGING "Uptake"	188	
P-32	EYE TUMOR LOCALIZATION		
Se-75	PANCREAS IMAGING		
Yb-169	CISTERNOGRAPHY		
Xe-133	BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES		
OTHER	I-123 Scan & Uptake (Thyroid)	38	
Tc-99m	BRAIN IMAGING	88	
	CARDIAC IMAGING Tc or Thallium	2472	
	THYROID IMAGING		
	SALIVARY GLAND IMAGING		
	BLOOD POOL IMAGING		
	PLACENTA LOCALIZATION		
	LIVER AND SPLEEN IMAGING	123	
	LUNG IMAGING	1129	
	BONE IMAGING	1298	
OTHER	GATED CARDIAC IMAGING (MUGA)	622	

(3)

PRECEPTOR STATEMENT (Continued)

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
P-32 (Soluble)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES		
P-32 (Colloidal)	INTRACAVITARY TREATMENT		
I-131	TREATMENT OF THYROID CARCINOMA	7	
	TREATMENT OF HYPERTHYROIDISM	72	
Au-198	INTRACAVITARY TREATMENT		
Co-60 or Cs-137	INTERSTITIAL TREATMENT		
	INTRACAVITARY TREATMENT		
I-125 or Ir-192	INTERSTITIAL TREATMENT		
	TELE THERAPY TREATMENT		
Co-60 or Cs-137	TELE THERAPY TREATMENT		
	TELE THERAPY TREATMENT		
Sr-90	TREATMENT OF EYE DISEASE		
	RADIO PHARMACEUTICAL PREPARATION		
Mo-99/ Tc-99m	GENERATOR		
Sr-113/ In-113m	GENERATOR		
Tc-99m	REAGENT KITS		
Other	Tc-99m GI Bleeding Study	10	
	Co-57/Co-58 Schilling Test		
	Tc-99m Gastric Emptying	159	
	Tc-99m GI Afflux		
	Tc-99m WBC Scans	19	
	Tc-99m Brain Spect		
	Tc-99m Meckel's Scan	4	

3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

Nuclear Medicine

1 mo Dec. 1991 2 mos 1994
2 mos 1992 1 1995

Total = 960 hrs

**4. THE TRAINING AND EXPERIENCE INDICATED ABOVE
WAS OBTAINED UNDER THE SUPERVISION OF:**

6. PRECEPTOR'S SIGNATURE

a. NAME OF SUPERVISOR

Raymundo T. Go, M.D.

Raymundo T. Go, M.D.

b. NAME OF INSTITUTION

Cleveland Clinic Foundation

7. PRECEPTOR'S NAME (Please type or print)

Raymundo T. Go, M.D.

c. MAILING ADDRESS Nuclear Medicine (Gb3)

9500 Euclid Ave.,

d. CITY

Cleveland, OH 44195

8. DATE

June 4, 1996

5. MATERIALS LICENSE NUMBER(S)

34-0046601

The American Board of Radiology

*Organized through the cooperation of the
American College of Radiology, the American Roentgen Ray Society,
the American Radium Society, the Radiological Society of North America,
the Section on Radiology of the American Medical Association,
the American Society for Therapeutic Radiology and Oncology, the Association of
University Radiologists, and American Association of Physicists in Medicine*

Hereby certifies that

Hareesh Arora, M.D.

*Has pursued an accepted course of graduate study
and clinical work, has met certain standards and qualifications and
has passed the examinations conducted under the authority of*

The American Board of Radiology

On this seventh day of November, 1995

*Thereby demonstrating to the satisfaction of the Board
that he is qualified to practice the specialty of*

Diagnostic Radiology



Douglas Maynard MD *William Jewell MD M. Paul Capp. M.D.*
President Secretary-Treasurer Executive Director



OCT 08 1996

Steve Cooksey, Director
Diagnostic Imaging
Lorain Community/St. Joseph
Regional Health Center
3700 Kolbe Road
Lorain, OH 44053

Dear Mr. Cooksey:

Enclosed is Amendment No. 34 to your NRC Material License No. 34-04474-01 in accordance with your request.

Please review the enclosed document carefully and be sure that you understand all conditions. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region III office at (630) 829-9887 so that we can provide appropriate corrections and answers.

Please be advised that your license expires at the end of the day, in the month, and year stated in the license. Unless your license has been terminated, you must conduct your program involving byproduct materials in accordance with the conditions of your NRC license, representations made in your license application, and NRC regulations. In particular, note that you must:

1. Operate in accordance with NRC regulations 10 CFR Part 19, "Notices, Instructions and Reports to Workers; Inspections," 10 CFR Part 20, "Standards for Protection Against Radiation," and other applicable regulations.
2. Notify NRC, in writing, within 30 days:
 - a. When an authorized user or Radiation Safety Officer permanently discontinues performance of duties under the license or has a name change;
 - b. When the licensee's mailing address changes (no fee is required if the location of byproduct material remains the same).
3. In accordance with 10 CFR 30.36(b) and/or license condition, notify NRC, promptly, in writing, and request termination of the license when you decide to terminate all activities involving materials authorized under the license.
4. Request and obtain a license amendment before you:
 - a. Receive or use byproduct material for a clinical procedure permitted under Part 35 but not permitted by your license issued pursuant to this Part;

301862

- b. Permit anyone, except individuals described in 10 CFR 35.13(b), to work as an authorized user under the license;
 - c. Change Radiation Safety Officers;
 * * * * *
 - d. Order byproduct material in excess of the amount, or radionuclide, or form different than authorized on the license;
 - e. Add or change the areas of use or address or addresses of use identified in the license application or on the license; or
 - f. Change ownership of your organization.
5. Submit a complete renewal application with proper fee or termination request at least 30 days before the expiration date of your license. You will receive a reminder notice approximately 90 days before the expiration date. Possession of byproduct material after your license expires is a violation of NRC regulations. A license will not normally be renewed, except on a case-by-case basis, in instances where licensed material has never been possessed or used.

In addition, please note that NRC Form 313 requires the applicant, by his/her signature, to verify that the applicant understands that all statements contained in the application are true and correct to the best of the applicant's knowledge. The signatory for the application should be the licensee or certifying official rather than a consultant.

You will be periodically inspected by NRC. Failure to conduct your program in accordance with NRC regulations, license conditions, and representations made in your license application and supplemental correspondence with NRC will result in enforcement action against you. This could include issuance of a notice of violation, or imposition of a civil penalty, or an order suspending, modifying or revoking your license as specified in the General Policy and Procedures for NRC Enforcement Actions. Since serious consequences to employees and the public can result from failure to comply with NRC requirements, prompt and vigorous enforcement action will be taken when dealing with licensees who do not achieve the necessary meticulous attention to detail and the high standard of compliance which NRC expects of its licensees.

Sincerely,
 Original Signed By
 Michael F. Weber
 Nuclear Materials Licensing Branch

License No. 34-044740-01
 Docket No. 030-02729

Enclosure: Amendment No. 34

DOCUMENT NAME: M:\03002729.CL6

To receive a copy of this document, indicate in the box: "C" = Copy without attachment/enclosure "E" = Copy with attachment/enclosure "N" = No copy

OFFICE	DNMS/RIII	<input checked="" type="checkbox"/>						
NAME	MFWeber:sjd <i>msw</i>							
DATE	10/3/96							

OFFICIAL RECORD COPY



UNITED STATES
NUCLEAR REGULATORY COMMISSION

REGION III
801 WARRENVILLE ROAD
LISLE, ILLINOIS 60532-4351

September 25, 1996

Thomas R. Martin, M.D.
Radiation Safety Officer
Lorain Community/St. Joseph
Regional Health Center
3700 Koble Road
Lorain, OH 44053

SUBJECT: ACKNOWLEDGEMENT OF CORRESPONDENCE
(Application Dated 09/03/96)

Dear Licensee:

In response to your request, we have completed the initial processing, which is an administrative review of your application for a(n):

☐ New License ☒ Amendment ☐ Renewal
☐ Termination ☐ Auth User (Amendment not required)
☐ Other _____

No administrative deficiencies were identified during this initial review. However, it should be noted that a technical review may identify omissions in the submitted information.

It appears that your request is routine (see 1-3 below, as applicable).

1. New and amendment actions are normally processed within 90 days, unless we find major deficiencies, or policy issues requiring central program office assistance.
2. Renewal actions are normally processed within 180 days, however, under timely filing (before expiration), you may continue to operate under your existing license.
3. Termination actions are normally processed within 90 days, unless confirmatory surveys following decontamination/decommissioning activities are involved.

A copy of your correspondence has been forwarded to our Licensing Fee and Debt Collection Branch (301/415-6097) for approval of the fee category and amount, if required.

If you have a compelling safety or business-related reason for requesting expedited review, please contact the Materials Licensing Branch at (630) 829-9887. We will try to complete your request as soon as practicable. Any correspondence about this request should reference the control number.

Nuclear Materials Support Branch

Mail Control No. 301862
License No. 34-04474-01